Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by M101on Jan 13, 2022 12:17pm
99 Views
Post# 34313114

RE:RE:RE:RE:RE:RE:Aduhelm stimulation

RE:RE:RE:RE:RE:RE:Aduhelm stimulation Yes but follow the money, it's incompetence and greed but not a scam because Gene and Elliot would make lot more by letting the price rise.

I think Elliot's final financing was the breaking point for some insiders, leading to the FSG purchase. And since then we've seen constant market buying leading to millions accumulated under Fidelity, which begs the question is there battle for control going on within? 

I mean it seems like Elliot was too picky about his placees, and there's always a placement clause stating that existing shareholders have the raight to maintain relative shares, so then market buying may be necessary to gain a control block.

So mornings like this, with pp holders dumping yet again, may be exactly what we need to see off our incompetent consultants plus their inside deadwood supporters.



 
<< Previous
Bullboard Posts
Next >>